BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Amyloidosis readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Amyloidosis\, from Cl
 inicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04270175-2289@assetmemo.bio
DTSTAMP:20261121T005603Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Daratumumab: Phase 2 readout est. (NCT04270175)
DESCRIPTION:Daratumumab\, phase 2\, AL Amyloidosis.\nStudy: Daratumumab\, P
 omalidomide\, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain A
 myloidosis Patients Previously Exposed to Daratumumab\nEstimated primary c
 ompletion: January 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/daratumumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04270175
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07388602-3146@assetmemo.bio
DTSTAMP:20261121T005603Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:SCTC21C: Phase 3 readout est. (NCT07388602)
DESCRIPTION:SCTC21C\, phase 3\, AL Amyloidosis.\nStudy: A Study to Evaluate
  the Safety and Efficacy of SCTC21C in Combination With Bortezomib\, Cyclo
 phosphamide\, and Dexamethasone in Patients With Newly Diagnosed Systemic 
 Light-Chain Amyloidosis (NDSLCA)\nEstimated primary completion: December 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/sctc21c#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07388602
URL:https://assetmemo.bio/drug/sctc21c#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07335887-2289@assetmemo.bio
DTSTAMP:20261121T005603Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Daratumumab: Phase 2 readout est. (NCT07335887)
DESCRIPTION:Daratumumab\, phase 2\, AL Amyloidosis.\nStudy: Sonrotoclax Plu
 s Dexamethasone With or Without Daratumumab Regimen in Patients With t(11\
 ;14) Primary AL Amyloidosis\nEstimated primary completion: 31 December 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07335887
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06158854-3229@assetmemo.bio
DTSTAMP:20261121T005603Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Etentamig: Phase 1/2 readout est. (NCT06158854)
DESCRIPTION:Etentamig\, phase 1/2\, AL Amyloidosis.\nStudy: A Study to Asse
 ss Change in Disease Activity and Adverse Events (AE)s in Adult Participan
 ts With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (A
 BBV-383) as an Intravenous (IV) Infusion\nEstimated primary completion: Fe
 bruary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/etentami
 g#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 158854
URL:https://assetmemo.bio/drug/etentamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07638683-2289@assetmemo.bio
DTSTAMP:20261121T005603Z
DTSTART;VALUE=DATE:20280730
DTEND;VALUE=DATE:20280731
SUMMARY:Daratumumab: Phase 2 readout est. (NCT07638683)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: A Phase II St
 udy to Evaluate the Efficacy and Safety of Teclistamab in Combination With
  Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurren
 t Light Chain Amyloidosis (MM+AL).\nEstimated primary completion: 30 July 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0763868
 3
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05898646-2289@assetmemo.bio
DTSTAMP:20261121T005603Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Daratumumab: Phase 2 readout est. (NCT05898646)
DESCRIPTION:Daratumumab\, phase 2\, AL Amyloidosis.\nStudy: Daratumumab Mai
 ntenance Therapy for Improving Survival in Patients With Light Chain Amylo
 idosis\, EMILIA Trial\nEstimated primary completion: 30 November 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05898646
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06022939-2289@assetmemo.bio
DTSTAMP:20261121T005603Z
DTSTART;VALUE=DATE:20300729
DTEND;VALUE=DATE:20300730
SUMMARY:Daratumumab: Phase 3 readout est. (NCT06022939)
DESCRIPTION:Daratumumab\, phase 3\, AL Amyloidosis.\nStudy: Comparing Dara-
 VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone 
 for People Who Have Newly Diagnosed AL Amyloidosis\nEstimated primary comp
 letion: 29 July 2030. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /daratumumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06022939
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07110844-2289@assetmemo.bio
DTSTAMP:20261121T005603Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:Daratumumab: Phase 2 readout est. (NCT07110844)
DESCRIPTION:Daratumumab\, phase 2\, AL Amyloidosis.\nStudy: Teclistamab-Dar
 atumumab in AL Amyloidosis\nEstimated primary completion: October 2031. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07110844
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07793422-3229@assetmemo.bio
DTSTAMP:20261121T005603Z
DTSTART;VALUE=DATE:20341231
DTEND;VALUE=DATE:20350101
SUMMARY:Etentamig: Phase 3 readout est. (NCT07793422)
DESCRIPTION:Etentamig\, phase 3\, AL Amyloidosis.\nStudy: Study to Evaluate
  Change in Disease Activity and Adverse Events of Subcutaneous Etentamig C
 ompared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexame
 thasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) Amyloidosis\
 nEstimated primary completion: December 2034. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/etentamig#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07793422
URL:https://assetmemo.bio/drug/etentamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
